Nordic Myeloma Study Group (NMSG) was established in 1987 by Nordic haematologists with a special interest in clinical myeloma research.
NMSG is an independent Nordic organization of research active MDs and Norwegian, Swedish, Icelandic, Finnish, Estonian, Lithuanian, and Danish clinics / hospitals who conduct clinical myeloma research. About 60 haematological clinics / hospitals - among these 25 university hospitals - from Norway, Sweden, Iceland, Finland and Denmark are part of NMSG. In addition to this clinics from Estonia and Lithuania participate in some of the clinical trials.
The vision of NMSG is to ensure optimal evidence-based treatment of all myeloma patients in the Nordic countries through e.g. population-based clinical and controlled studies with associated basic research on the disease and its biology.
NMSG works for this vision by
- Conducting comprehensive Phase III trials including all aspects of the myeloma disease with focus on life quality of the patients.
- Conducting Phase II trials in well characterized patient groups supported by lab research.
- Establishing a knowledge network about the myeloma disease and the treatment thereof for clinically working MDs, nurses, myeloma patients and their relatives.
Organizationally NMSG consists of a President, an Executive Board, regional coordinators and members. The Nordic countries take turns regarding the presidency.
The Executive Board consists of 14 members: 3 are from Norway, Sweden and Denmark respectively. 2 members are from Finland, and 1 member from Iceland, Estonia and Lithuania respectively.
See diagram of NMSG's organisation: Diagram 2017.pdf
Hareth Nahi, (Vice president), Karolinska University Hospital, Huddinge Sjukhus
Cecilie Hveding Blimark, Sahlgrenska Sjukhus, Gothenburg
Markus Hansson, Skåne University Hospital, Lund
Niels Abildgaard, Odense University Hospital - national coordinator.
Annette Vangsted, (President) Rigshospitalet, Copenhagen
Henrik Gregersen, Aalborg University Hospital
Edward Laane, North Estonia Medical Centre, Tallin
Juha Lievonen, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
Mervi Putkonen, Turku University Hospital
Raija Silvennoinen, Helsinki University Hospital
Sigurdur Yngvi Kristinsson, The National University Hospital of Iceland - national coordinator.
Valdas Pečeliūnas, Vilnius University Hospital
Anders Waage, St. Olavs Hospital, Trondheim Universitetssykehus - national coordinator.
Einar Haukås, Stavanger Universitetssykehus
Nina Gulbrandsen, Oslo Universitetssykehus, Rikshospitalet
Associated to the executive board:
Peter Gimsing, (treasurer), Rigshospitalet, Copenhagen
The national NMSG coordinators are made up of 27 coordinating clinical researchers who are divided between the regional hospital regions with 6 regional coordinators in Norway, 9 in Sweden, 1 in Iceland, 6 in Denmark and 5 in Finland.
At present (2018), NMSG members are made up of 368 clinical researchers and MDs with an interest in myeloma.
NMSG holds biannual plenary meetings with a scientific, educational and organizational agenda. All NMSG members may participate in the plenary meetings. NMSG sponsors are invited to participate in the plenary meetings.